Skip to content
Disclosery

GREAT POINT PARTNERS LLC

Follow

13F filer, CIK 1281446, Greenwich, CT

GREAT POINT PARTNERS LLC reported $153,801,796 across 26 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14. Its ten largest share positions make up 66.56% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001172661-25-003478

Period
2025-06-30
Reported value
$154M
Holdings
26
Top 10 weight
66.56%
New
6
Sold out
12

Largest buys vs the previous quarter

SecurityShares changeApprox. value
IONSadded+250,000$9.88M
RZLTadded+2,200,420$9.81M
LEGNadded+211,760$7.52M
AKROnew+103,848$5.54M
JBIOnew+498,054$4.98M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AKBAreduced-2,987,925-$10.9M
VRDNexited-750,000-$10.1M
MERUS N Vexited-237,156-$9.98M
KALVreduced-691,197-$7.81M
ASNDexited-50,000-$7.79M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0001172661-25-003478, largest first. % of portfolio is the value over $153,801,796, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
IONSIONIS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 255,000 shares; 2024Q4: 505,007 shares; 2025Q1: 250,000 shares; 2025Q2: 500,000 shares 500,000$19.8M12.84%+250,000Timeline
RZLTREZOLUTE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 621,894 shares; 2025Q1: 833,042 shares; 2025Q2: 3,033,462 shares 3,033,462$13.5M8.8%+2,200,420Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,811,996 shares; 2025Q2: 2,000,000 shares 2,000,000$12.8M8.34%+188,004Timeline
LEGNLEGEND BIOTECH CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 138,240 shares; 2025Q2: 350,000 shares 350,000$12.4M8.08%+211,760Timeline
ABVXABIVAX SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,128,773 shares; 2024Q4: 1,648,523 shares; 2025Q1: 1,638,111 shares; 2025Q2: 1,291,617 shares 1,291,617$9.88M6.42%-346,494Timeline
NGNENEUROGENE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,004,291 shares; 2024Q4: 442,761 shares; 2025Q1: 470,964 shares; 2025Q2: 485,859 shares 485,859$7.26M4.72%+14,895Timeline
AKBAAKEBIA THREAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 4,973,840 shares; 2025Q2: 1,985,915 shares 1,985,915$7.23M4.7%-2,987,925Timeline
EOLSEVOLUS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,170,000 shares; 2024Q4: 895,524 shares; 2025Q1: 944,743 shares; 2025Q2: 720,118 shares 720,118$6.63M4.31%-224,625Timeline
ACLXARCELLX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 100,000 shares; 2024Q4: not reported; 2025Q1: 45,000 shares; 2025Q2: 100,000 shares 100,000$6.58M4.28%+55,000Timeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 245,272 shares; 2025Q1: 245,272 shares; 2025Q2: 200,000 shares 200,000$6.26M4.07%-45,272Timeline
AKROAKERO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 103,848 shares 103,848$5.54M3.6%newTimeline
JBIOJADE BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 498,054 shares 498,054$4.98M3.24%newTimeline
CYTKCYTOKINETICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 316,000 shares; 2024Q4: 360,000 shares; 2025Q1: 370,000 shares; 2025Q2: 150,000 shares 150,000$4.96M3.22%-220,000Timeline
IMVTIMMUNOVANT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 375,000 shares; 2025Q2: 262,176 shares 262,176$4.19M2.73%-112,824Timeline
UNCYUNICYCIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 796,558 shares 796,558$3.8M2.47%newTimeline
KALVKALVISTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,299,503 shares; 2024Q4: 1,787,003 shares; 2025Q1: 1,014,367 shares; 2025Q2: 323,170 shares 323,170$3.65M2.38%-691,197Timeline
TSHATAYSHA GENE THERAPIES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 1,500,000 shares 1,500,000$3.46M2.25%newTimeline
DBVTDBV TECHNOLOGIES S AQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 374,679 shares 374,679$3.43M2.23%newTimeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 3,263,672 shares; 2024Q4: 3,170,194 shares; 2025Q1: 3,170,194 shares; 2025Q2: 3,170,194 shares 3,170,194$3.33M2.16%0Timeline
UPBUPSTREAM BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 300,000 shares; 2025Q1: 300,000 shares; 2025Q2: 300,000 shares 300,000$3.29M2.14%0Timeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 6,934,982 shares; 2024Q4: 4,683,711 shares; 2025Q1: 4,683,711 shares; 2025Q2: 4,683,711 shares 4,683,711$3.07M2%0Timeline
CNTACENTESSA PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 149,702 shares; 2025Q2: 225,000 shares 225,000$2.96M1.92%+75,298Timeline
SRRKSCHOLAR ROCK HLDG CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 61,607 shares 61,607$2.18M1.42%newTimeline
PROMIS NEUROSCIENCES INCPROMIS NEUROSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,790,698 shares; 2024Q4: 2,645,128 shares; 2025Q1: 2,645,128 shares; 2025Q2: 2,645,128 shares 2,645,128$1.28M0.83%0
PLRXPLIANT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,910,121 shares; 2024Q4: 1,055,000 shares; 2025Q1: 850,000 shares; 2025Q2: 850,000 shares 850,000$986K0.64%0Timeline
HELIX ACQUISITION CORP IIHELIX ACQUISITION CORP IIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 500,000 shares; 2024Q4: 500,000 shares; 2025Q1: 373,833 shares; 2025Q2: 29,381 shares 29,381$312K0.2%-344,452

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
VRDNVIRIDIAN THERAPEUTICS INC750,000$10.1Mshares
MERUS N VMERUS N V237,156$9.98Mshares
ASNDASCENDIS PHARMA A/S50,000$7.79Mshares
DVAXDYNAVAX TECHNOLOGIES CORP595,879$7.73Mshares
UNICYCIVE THERAPEUTICS INCUNICYCIVE THERAPEUTICS INC10,980,000$6.31Mshares
DNTHDIANTHUS THERAPEUTICS INC275,000$4.99Mshares
SMMTSUMMIT THERAPEUTICS INC250,000$4.82Mput
PCVXVAXCYTE INC115,517$4.36Mshares
AUTLAUTOLUS THERAPEUTICS LTD2,728,910$4.23Mshares
BEAMBEAM THERAPEUTICS INC175,562$3.43Mshares
MREOMEREO BIOPHARMA GROUP PLC1,275,000$2.87Mshares
VYGRVOYAGER THERAPEUTICS INC626,275$2.12Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001172661-25-003478 base2025-08-14acceptance time not in the bulk data set